Stimulants: Cocaine and Methamphetamine

CRIT/FIT program – April 2016

Alex Walley, MD, MSc
Learning objectives

At the end of this session, participants will be able to:

1. Understand how and why people use stimulants
2. Know the characteristics of stimulant intoxication and withdrawal syndromes
3. Understand the consequences of these drugs
4. Know the current options for treatment of stimulant dependence
History: Cocaine

- From erythroxylon coca leaves in Andes
- Leaves chewed for thousands of years as stimulant
- 1884 Freud published, *Uber Coca*, describing cocaine’s effects on Freud and its potential to treat opiate addiction
- 1885 Halsted published study about anesthetic uses
- 1886 Halsted raided ship medicine cabinet for fix
- Used in medicines and beverages until early 1900s
- Street preparations 10-50% cocaine
  - Hydrochloride powder is snorted or injected
  - Alkaline rocks (aka crack) are smoked
  - Crack, Rock, Base
History: Methamphetamine

• 1893 methamphetamine first synthesized in Japan as decongestant

• Used by German, English, American, and Japanese military in WWII for performance enhancement.

• First epidemic occurred in Japan when the military dumped large quantities into the civilian market

• Popular among truckers and west coast bikers in 1970s

• DESOXYN to treat ADHD and obesity

• *Speed, Crystal, Crank, Ice, Meth, Tina*
Epidemiology
2005 drug-related ED visits

Drug Abuse Warning Network 2005 Report
From where do these drugs come?

- Methamphetamine
  - Super labs – Primarily Mexico
  - Local clandestine labs - 1 pound of MA creates 6 pounds of toxic waste

- Cocaine -
  - 75% grown in Colombia with 75% via Mexico/ Central America

http://www.colombiajournal.org/cocainephotos.htm
Clandestine lab incidents

Total of All Meth Clandestine Laboratory Incidents
Including Labs, Dumpsites, Chem/Glass/Equipment
Calendar Year 2004

Source: National Clandestine Laboratory Database
Total: 15,994 / 49 States Reporting
Dates: 01/01/04 to 12/31/04

Total of All Meth Clandestine Laboratory Incidents
Including Labs, Dumpsites, Chem/Glass/Equipment
Calendar Year 2006

Source: National Clandestine Laboratory Database
Total: 6,435
Dates: 01/01/2006 - 12/31/2006

www.dea.gov
Stimulant Effects
Why do people use stimulants?

• Euphoria - Rush
  • Onset and intensity depends on delivery method
• Increased energy, alertness, libido
• Diminished social inhibition
• Decreased appetite
### PK: Cocaine

<table>
<thead>
<tr>
<th></th>
<th>IV</th>
<th>Smoked</th>
<th>Snorted</th>
</tr>
</thead>
<tbody>
<tr>
<td>Time to effect</td>
<td>10-60 sec</td>
<td>3-5 sec</td>
<td>1-5 min</td>
</tr>
<tr>
<td>Peak concent.</td>
<td>3-5 min</td>
<td>1-3 min</td>
<td>15-20 min</td>
</tr>
<tr>
<td>Half-life</td>
<td>20-60 min</td>
<td>5-15 min</td>
<td>60-90 min</td>
</tr>
</tbody>
</table>


### PK: Methamphetamine

<table>
<thead>
<tr>
<th></th>
<th>IV</th>
<th>Smoked</th>
<th>Snorted</th>
<th>Ingested</th>
</tr>
</thead>
<tbody>
<tr>
<td>Time to effect</td>
<td>15-30 sec</td>
<td>Immediate</td>
<td>3-5 min</td>
<td>15-20 min</td>
</tr>
<tr>
<td>Peak concent.</td>
<td>2-4 h</td>
<td>2-4 h</td>
<td>2-4 h</td>
<td>2-4 h</td>
</tr>
<tr>
<td>Half-life</td>
<td>10-12 h</td>
<td>10-12 h</td>
<td>10-12 h</td>
<td>10-12 h</td>
</tr>
</tbody>
</table>

Lineberry 2006
Cocaine Euphoria
Positive Reinforcement
Activated Reward Pathways
\[
\text{DA/Glutamate}
\]
Cocaine Craving
Negative Reinforcement
\[
\text{DA/Glutamate}
\]
Cocaine Cues
Limbic Activation
\[
\text{DA/Glutamate}
\]
Loss of Control
Denial / Poor Decision-Making
Hypofrontality / Low D2
Reduced Gray Matter Density
Cocaine Administration
Drug-Seeking Behavior
Failed Impulse Suppression
Multiple Risks/Hazards
Reward Dysregulation
Cocaine Withdrawal
\[
\text{DA/Glutamate}
\]
\[
\text{Dynorphin/GABA}
\]
Dynamic Cycle of Cocaine Addiction
Slide from Nadia Fairbairn
Binges

• 2-3 day binges are typical, called runs
• Regular re-dosing to maintain rush or high in setting of acute tolerance
• Ends when drug or money runs out, or paranoia/disorganized thinking sets in
Acute Toxicity

- Elevated BP and HR
- Arrythmia
- Vasoconstriction
- Hyperthermia

- Agitation
- Rhabdomyolysis
- Seizure

- Acute psychosis → prolonged psychosis
  - Paranoid delusions
  - Visual, sensory, and auditory hallucinations
    - ie formications
Intoxication Treatment

• Minimize sensory stimulation
• Neuroleptics (ie haldol) for agitation
• Benzos to control seizures
• Treat hyperthermia (external cooling)
• For increased BP+HR, use vasodilators and CCB or non-selective beta-blockers
Is there stimulant withdrawal?

- Intense craving
- Depression
- Fatigue
- Unpleasant dreams
- Hypersomnia, then insomnia
- Increased appetite
- Limited ability to experience pleasure

>> All results of relative dopamine depletion
Health Consequences
<table>
<thead>
<tr>
<th>Category</th>
<th>Conditions</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Dental</strong></td>
<td>Darkened teeth, Caries, Periodontal disease</td>
</tr>
<tr>
<td><strong>Skin</strong></td>
<td>Cellulitis/ abscess, Excoriations, Chemical burns</td>
</tr>
<tr>
<td><strong>Pulmonary</strong></td>
<td>Acute pulmonary edema, Pulmonary HTN, Inhalation injury</td>
</tr>
<tr>
<td><strong>Cardiovascular</strong></td>
<td>Hypertension, DCM, Arrhythmia/ Tachycardia, Acute Coronary Syndrome, Aneurysm/ dissection, Erectile dysfunction</td>
</tr>
<tr>
<td><strong>Neuro-psychiatric</strong></td>
<td>Stroke, Seizure, Depression, Anxiety, Mania, Impulsivity, Paranoia, Auditory/ visual hallucinations + formications, Violence</td>
</tr>
<tr>
<td><strong>Renal/Metabolic</strong></td>
<td>Rhabdomyolisis, Dehydration, Acute Renal Failure, Acidosis, Hyperthermia</td>
</tr>
<tr>
<td><strong>Infectious</strong></td>
<td>HIV risk, HCV/ HBV, STDs</td>
</tr>
</tbody>
</table>
ETOH + Cocaine >> Cocaethylene

- Psychoactive substrate from ETOH+cocaine
- ETOH commonly used as “landing gear”
- ETOH before cocaine inhibits cocaine metabolism, producing cocaethylene
- 60-90% of cocaine abusers abuse ETOH
- Greater cardiac toxicity
- Greater rates of seizures, hepatic damage
Treatment
Anticonvulsants for cocaine dependence (Review)

Minozzi S

Efficacy of Psychostimulant Drugs for Cocaine Dependence (Review)

Efficacy of psychostimulant drugs for amphetamine abuse or dependence (Review)

Castells X

Dopamine agonists for the treatment of cocaine dependence (Review)

Antipsychotic medications for cocaine dependence (Review)

Minozzi S, Amato I

Disulfiram for the treatment of cocaine dependence (Review)

Antidepressants for cocaine dependence and problematic cocaine use (Review)

Pani PP, Trogu E, Vecchi S, Amato I
Topiramate for the Treatment of Cocaine Addiction
A Randomized Clinical Trial

Bankole A. Johnson, DSc, MD; Nassima Ait-Daoud, MD; Xin-Qun Wang, MS; J. Kim Penberthy, PhD;
Martin A. Javors, PhD; Charnind Seneviratne, MD; Lei Liu, PhD

IMPORTANCE No medication has been established as an efficacious treatment for cocaine dependence. We hypothesized that dual modulation of the mesocorticolimbic dopamine system by topiramate—a glutamate receptor antagonist and γ-aminobutyric acid receptor agonist—would result in efficacious treatment for cocaine dependence compared with placebo.

OBJECTIVE To determine the efficacy of topiramate vs placebo as a treatment for cocaine dependence.

DESIGN, SETTING, AND PARTICIPANTS Double-blind, randomized, placebo-controlled, 12-week trial of 142 cocaine-dependent adults in clinical research facilities at the University of Virginia between November 22, 2005, and July 25, 2011.

INTERVENTIONS Topiramate (n = 70) or placebo (n = 72) in escalating doses from 50 mg/d to the target maintenance dose of 300 mg/d in weeks 6 to 12, combined with weekly cognitive-behavioral treatment.

MAIN OUTCOMES AND MEASURES For the efficacy period, weeks 6 to 12, the primary outcome was the weekly difference from baseline in the proportion of cocaine nonuse days; the secondary outcome was urinary cocaine-free weeks, and exploratory outcomes included craving and self- and observer-rated global functioning on the Clinical Global Impression scales.

RESULTS Using an intent-to-treat analysis, topiramate was more efficacious than placebo at increasing the weekly proportion of cocaine nonuse days, irrespective of whether missing data were not or were imputed conservatively to the baseline value (13.3% vs 5.3%; 95% CI for the estimated mean difference, .1%-14.6%; P = .02 or 8.9% vs 3.7%; 95% CI for the estimated mean difference, 0.2%-10.1%; P = .04, respectively). Topiramate also was associated, significantly more than placebo, with increasing the likelihood of urinary cocaine-free weeks (16.6% vs 5.8%; odds ratio, 3.21; 95% CI, 1.24-8.32; P = .02), as well as decreasing craving and improving observer-rated global functioning (all P < .05).

CONCLUSIONS AND RELEVANCE Topiramate is more efficacious than placebo at increasing the mean weekly proportion of cocaine nonuse days and associated measures of clinical improvement among cocaine-dependent individuals.

TRIAL REGISTRATION clinicaltrials.gov Identifier: NCT00249691

Author Affiliations: Department of Psychiatry and Neurobehavioral Sciences, University of Virginia, Charlottesville (Johnson, Ait-Daoud, Penberthy, Seneviratne); now with Department of Psychiatry, University of Maryland School of Medicine, Baltimore (Johnson); Department of Public Health Sciences, University of Virginia, Charlottesville (Wang); Department of Psychiatry, The University of Texas Health Science Center, Houston (Javors, Liu).
Topiramate for the treatment of methamphetamine addiction: a multi-center placebo-controlled trial

Ahmed Elkashef1, Roberta Kahn1, Elmer Yu1, Erin Iturriaga1, Shou-Hua Li1, Ann Anderson1, Nora Chiang1, Nasimia Ait-Daoud1, David Weiss4, Frances McSherry4, Tracey Serpi5, Richard Rawson5, Mark Hymo6, Dennis Weis4, Michael McCann1, Tony Pham1, Christopher Stock6, Ruth Dickinson3, Jan Campbell3, Charles Gorodetsky3, William Haning16, Barry Carlson16, Joseph Mawhiney16, Ming D. Li16 & Bankole A. Johnson1

National Institute on Drug Abuse, National Institutes of Health, Bethesda, MD, USA, Veterans Administration Medical Center, Philadelphia, PA, USA, Department of Psychiatry and Neurobehavioral Sciences, University of Virginia, Charlottesville, VA, USA, Department of Veterans Affairs Cooperative Studies Program Coordinating Center, Perry Point, MD, USA, UCLA Integrated Substance Abuse Programs, Los Angeles, CA, USA, Lutheran Hospital Office of Research, Los Angeles, CA, USA, Martin Institute on Addictions, Costa Mesa, CA, USA, Department of Veterans Affairs Salt Lake City Health Care System, Salt Lake City, UT, USA, Department of Psychiatry, University of Missouri, Kansas City, MO, USA, Pacific Addiction Research Center, Honolulu, HI, USA, and South Bay Treatment Center, San Diego, CA, USA

ABSTRACT

Aims Topiramate has shown efficacy at facilitating abstinence from alcohol and cocaine abuse. This double-blind, placebo-controlled outpatient trial tested topiramate for treating methamphetamine addiction. Design Participants (n = 140) were randomized to receive topiramate or placebo (13 weeks) in escalating doses from 50 mg/day to the target maintenance of 200 mg/day in weeks 6–12 (tapered in week 13). Medication was combined with weekly brief behavioral compliance enhancement treatment. Setting The trial was conducted at eight medical centers in the United States. Participants One hundred and forty methamphetamine-dependent adults took part in the trial. Measurements The primary outcome was abstinence from methamphetamine during weeks 6–12. Secondary outcomes included use reduction versus baseline, as well as psychosocial variables. Findings In the intent-to-treat analysis, topiramate did not increase abstinence from methamphetamine during weeks 6–12. For secondary outcomes, topiramate reduced weekly median urine methamphetamine levels and observer-rated severity of dependence scores significantly. Subjects with negative urine before randomization (n = 26) had significantly greater abstinence on topiramate versus placebo during study weeks 6–12. Topiramate was safe and well tolerated. Conclusions Topiramate does not appear to promote abstinence in methamphetamine users but can reduce the amount taken and reduce relapse rates in those who are already abstinent.
Non-medical treatment for addiction

• Physician advice and brief intervention
  • Evidence is limited to non-dependent, risky alcohol use
  • Except Bernstein et al. DAD 2005: 77; 49
• Motivational enhancement therapy
• Cognitive behavior therapy
• Community Reinforcement Approach/ Community Reinforcement and Family Therapy (CRAFT)
• 12-step facilitation
• Contingency management

All treatments require adherence
A Meta-Analytic Review of Psychosocial Interventions for Substance Use Disorders

Dutra et al., Am J Psychiatry, 2008

FIGURE 1. Mean Effect Sizes Across Substance Use Disorders Under Treatment

FIGURE 2. Mean Effect Sizes Across Treatment Types
• 487 cocaine-dependent outpatients.

• 12-step active participation (i.e. speaking at meetings, working the steps, having a sponsor) predicted reduced cocaine use in the following month.

• 12-step meeting attendance did not predict subsequent drug use.
Contingency Management

Systematic Review – Schierenberg 2012 – 19 studies
• CM in combination with other treatment
  • Increases cocaine abstinence
  • Improves treatment retention
  • May act synergistically with medications

RCT in 6 community methadone programs of CM among stimulant users
• Usual Care vs.
• Intermittent, escalating re-enforcement
  • 1000 chips
    • 500 “Good job”
    • 250 “Small” - $1 value – i.e. toiletries
    • 209 “Large” - $20 value – i.e. kitchenware
    • 1 “Jumbo” – $80-100 value – tv, stereo
  • # of draws = # of weeks with clean urine

The mean percentage of submitted samples testing negative for target drugs (stimulants and alcohol) is shown for abstinence incentive and usual care participants at each of 24 study visits.

Average cost = $1.46 per person/day
Cocaine use at beginning of buprenorphine treatment

**FIGURE 1.** Buprenorphine treatment retention by baseline cocaine use.

**FIGURE 2.** Self-reported opioid use among participants who initiated buprenorphine treatment by baseline cocaine use.

What should we do with our stimulant-using patients?

• Ask and educate about medical complications, overdose
• Harm reduction – safer use techniques
• Recommend psychosocial treatment, especially contingency management

• Methylphenidate, topiramate and naltrexone have shown some promise, but no medications have shown consistent, convincing evidence for effectiveness
• Advocate, research and develop novel strategies in the treatment of stimulant use disorders
Learning objectives

At the end of this session, participants will be able to:

1. Understand how and why people use stimulants
2. Know the characteristics of stimulant intoxication and withdrawal syndromes
3. Understand the consequences of these drugs
4. Know the current options for treatment of stimulant dependence
Thanks!

Alex Walley, MD, MSc
awalley@bu.edu
AHA 2011 Updated Scientific Statement on cocaine and methamphetamine unstable angina/NSTEMI

• **Class I: Benefit >>> Risk**
  • NTG and CCB for ST changes (Level C)
    • Immediate cath if ST remain elevated after NTG and CCB (Level C)
      • Fibrinolytics if cath not available
  • NTG + CCB for normal ECGs or minimal ST changes (Level C)
  • Cath for new persistent ST changes after NTG + CCB (Level C)
  • Manage methamphetamine similarly to cocaine UA

• **Class IIa: Benefit >> Risk**
  • NTG + CCB for normal ECGs or minimal ST changes (Level C)
  • Cath for new persistent ST changes after NTG + CCB (Level C)

• **Class IIb: Benefit ≥ Risk**
  • Non-selective beta-blockers for bp > 150/100 or HR > 100 after NTG or CCB

• **Class III: Risk ≥ Benefit**
  • Cath with no ST changes and negative stress test and troponins

Wright et al. JACC. 2011: 57; e215-367

All guidelines are Class 3 LIMITED evidence
Beta-Blockers in Cocaine Chest Pain

331 patients with chest pain and cocaine-positive urine test results admitted to San Francisco General Hospital between 2001-05

- 151 patients received a beta-blocker in ED
  - 85% received metoprolol

- During the hospitalization
  - SBP decreased more in ED beta-block group
  - No differences in ECG results, troponin levels, intubation rates, vasopressor use, malignant ventricular arrhythmia rates, or death were found.

- 45 deaths over a median follow-up of 972 days
  - Discharge on a beta-blocker regimen was associated with a lower risk of cardiovascular-specific death but not all-cause mortality

Pharmacologic Treatment

• Antipsychotics
  • Amato. Cochr Database Syst Rev. 2007 Jul 18;(3):
• Anticonvulsants - GABA modulators
  • Carbamazepine, Phenytoin, Valproic Acid, Tigabine, Gabapentin, Lamotrigine – Alvarez. JSAT 2010:38;66-73.
  • Baclofen — Heinzerling. Drug Alcohol Depend. 2006 Dec 1;85(3):177-84.
  • Topiramate — Ekashef Addiction 2012: 107;1297-1306.

• Stimulant replacement
  • Dexamphetamine – Longo. Addiction 2009, 105, 146–154
• Vaccine
Does crack make people more violent than powder cocaine?

Table 2:

<table>
<thead>
<tr>
<th>Violent behaviors</th>
<th>Powdered Cocaine</th>
<th>Crack Cocaine</th>
<th>Odds Ratio(^b) (unadjusted)</th>
<th>Odds Ratio(^c) (adjusted)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>% (95% CI(^a))</td>
<td>% (95% CI)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bully/push people</td>
<td>17.44(15.26–19.87)</td>
<td>23.27(19.01–28.17)</td>
<td>1.44 (1.04–1.97)</td>
<td>.82(.57–1.19)</td>
</tr>
<tr>
<td>Do things that could have easily hurt you/others</td>
<td>46.01(42.66–49.41)</td>
<td>55.26(49.02–61.33)</td>
<td>1.45 (1.07–1.96)</td>
<td>1.24(.84–1.84)</td>
</tr>
<tr>
<td>Rob/mug someone or snatch a purse</td>
<td>1.78(1.19–2.64)</td>
<td>4.55(2.66–7.71)</td>
<td>2.63 (1.35–5.12)</td>
<td>.89(.41–1.93)</td>
</tr>
<tr>
<td>Force someone to have sex</td>
<td>.63(.33–1.20)</td>
<td>2.36(.91–5.93)</td>
<td>3.78(1.19–12.00)</td>
<td>2.56(.71–9.21)</td>
</tr>
<tr>
<td>Get into lots of fights that you started</td>
<td>9.42(7.90–11.20)</td>
<td>15.36(12.01–19.44)</td>
<td>1.74(1.24–2.43)</td>
<td>.85(.56–1.29)</td>
</tr>
<tr>
<td>Get into a fight that came to swapping blows with husband/wife or boyfriend/girlfriend</td>
<td>17.98(15.59–20.66)</td>
<td>34.47(29.19–40.16)</td>
<td>2.40 (1.76–3.27)</td>
<td>1.55 (1.05–2.28)</td>
</tr>
<tr>
<td>Use a weapon in a fight</td>
<td>8.92(7.48–10.60)</td>
<td>19.87(15.84–24.63)</td>
<td>2.53 (1.83–3.50)</td>
<td>1.18(.80–1.73)</td>
</tr>
<tr>
<td>Hit someone so hard that you injure them</td>
<td>20.48(18.16–23.01)</td>
<td>30.01(24.57–36.07)</td>
<td>1.66 (1.23–2.25)</td>
<td>.79(.53–1.18)</td>
</tr>
<tr>
<td>Harass/threaten/blackmail someone</td>
<td>6.80(5.56–8.29)</td>
<td>12.27(9.20–16.20)</td>
<td>1.92 (1.34–2.74)</td>
<td>.93(.59–1.46)</td>
</tr>
<tr>
<td>Hurt an animal on purpose</td>
<td>5.59(4.44–7.02)</td>
<td>8.78(6.09–12.51)</td>
<td>1.63 (1.04–2.54)</td>
<td>.88(.55–1.40)</td>
</tr>
</tbody>
</table>

Note: \(^a\)CI: confidence interval, \(^b\)OR: odds ratio, \(^c\)Odds ratios adjusted for sociodemographic characteristics, lifetime mood and alcohol and substance use disorders, OR values in bold are statistically significant.

Contingency Management

Methadone Maintenance Patients With Specified Weeks of Continuous Stimulant/Alcohol-Negative Samples (n=388)

![Bar chart showing incentives and control group percentages for 4 weeks, 8 weeks, and 12 weeks.]

Average cost = $1.46 per person/day

Pierce et al. Arch Gen Psychiatry. 2006;63:201-208.
Studies of the treatment for cocaine-related unstable angina with beta-blockers…

1. include randomized controlled trials that demonstrate that they save lives
2. include randomized controlled trials that demonstrate that they cause harm
3. include catheter studies in humans that show improved vasospasm with propranolol
4. include observational studies that show no increased adverse events among people receiving beta-blockers in the ED
Which statement is true about stimulants?

1. Methamphetamine is only used intravenously or smoked
2. Methamphetamine has a longer half-life than cocaine
3. Intravenous injection results in the fastest onset of action
4. Cocaine’s peak concentration occurs in about 1 hour
5 things about stimulants

1. Easily available
2. Directly activate the mesolimbic pleasure center
3. Binge use often ends with dysphoria or lack of funds
4. Social and medical consequences
5. Treatment can work if you can find it
Dopamine release: nucleus accumbens

% basal dopamine in rat/mouse NA after:

- Food
- Sex
- Alcohol
- Nicotine
- Cocaine
- MA
Natural Rewards Elevate Dopamine Levels

**FOOD**

NAcc shell

% of Basal DA Output

- Empty Box
- Feeding

Time (min)

Source: Di Chiara et al.

**SEX**

DA Concentration (% Baseline)

Sample Number

- Sc 1
- Female 1 Present
- Sc 2
- Female 2 Present

Mounts
- Intromissions
- Ejaculations

Source: Fiorino and Phillips

Slide from Richard Rawson
Effects of Drugs on Dopamine Release

**METHAMPHETAMINE**

- Graph showing % of Basal Release over time after Methamphetamine administration.
- Peak response observed at 1 hr, followed by a decline.

**COCAINE**

- Graph showing % of Basal Release for DA, DOPAC, and HVA over time after Cocaine administration.
- Peak response observed for DA, DOPAC, and HVA at different times.

**NICOTINE**

- Graph showing % of Basal Release for Accumbens and Caudate over time after Nicotine administration.
- Response observed at 1 hr, followed by a decline.

**ETHANOL**

- Graph showing % of Basal Release over time after Ethanol administration.
- Different doses (0.25, 0.5, 1, 2.5 g/kg ip) show varying responses.

Source: Shoblock and Sullivan; Di Chiara and Imperato.

Slide from Richard Rawson.
Pregnancy

• More common in stimulant users:
  • Mental illness, seizure, injury, hypertension
  • Premature membrane rupture and labor, placenta previa, placental abruption, intrauterine death

• 1998-2004
  • Cocaine-related hosp decreased: 0.74>>0.41 per 100
  • MA-related hosp increased: 0.11>>0.22 per 100

• Cocaine vs. MA related pregnancy
  • More common for cocaine: mental illness, poor fetal growth, and premature delivery
  • More common for MA: hypertension, placenta previa

Cardiomyopathy and Methamphetamine

- In a case-control study, researchers examined the association between methamphetamine use and cardiomyopathy (CM).

- Subjects included patients aged 45 years or younger discharged from a tertiary care medical center in Honolulu.

- Through medical record review, researchers identified...
  - 107 cases (had a discharge diagnosis of CM or congestive heart failure) and
  - 114 controls (ejection fraction ≥55% and no wall motion abnormalities).

Cardiomyopathy and Methamphetamine

• 42% of cases and 20% of controls had ever used methamphetamine.
• Methamphetamine use was significantly more common in cases than in controls.
• OR in analyses adjusted for age, body mass index, and renal failure, 3.7

“No lies here folks this recipe will manufacture methamphetamine this will get you into trouble if you do this BE CAREFUL!”

First of all let's talk about supplies:

- 1 Case Regular Pint size Mason Jars (Used for canning)
- 2 Boxes Contact 12 hour time released tablets
- 3 Bottles of Heet.
- 4 feet of surgical tubing.
- 1 Bottle of Rubbing Alcohol.
- 1 Gallon Muriatic Acid (Used for cleaning concrete)
- 1 Gallon of Coleman's Fuel
- 1 Gallon of Aceton
- 1 Pack of Coffee Filters
- 1 Electric Skillet
- 4 Bottles Iodine Tincture 2%
- 2 Bottles of Hydrogen peroxide
- 3 20 oz Coke Bottles (Plastic type)(with Lids/caps)
- 1 Can Red Devils Lye
- 1 Pair of sharp scissors
- 4 Boxes Book Matches (try to get the ones with brown/red striker pads)
- 1 pyrodex baking dish
- 1 Box execto razor blades single sided
- 1 digital scale that reads grams
- 2 gallons distilled water
- 1 Roll Aluminum foil tape

“That's what you would have to go buy if you wanted to make meth.”

Cocaine and HIV

• Crack cocaine use is associated
  • increased number of sex partners
  • sex work
  • HIV infection, independent of IVD use

• IV cocaine leads to HIV through frequent injection Chaisson. JAMA. 1989 Jan 27;261(4):561-5.
MA and HIV

• Increased libido, social disinhibition, increased energy >> riskier sex behaviors
• PDE5 inhibitors (sildenafil) can be used to mitigate MA-induced erectile dysfunction
Methamphetamine and Trauma

To assess the prevalence and impact of methamphetamine use (MU) in trauma patients, researchers surveyed the records of...

- 4932 patients who presented to
  - San Diego trauma center between 2003–2005
  - urine toxicology screening during their visit

Results

• The rate of MU (defined as a positive urine screen), but not other illicit drug use, increased from 2003 to 2005 (from 9% to 15%).

• In adjusted analyses, patients with MU were more likely to have…

  • been injured in a violent way (OR, 2.0),
  • attempted suicide (OR, 1.7),
  • been a victim of domestic violence (OR, 2.5),
  • required more medical care (e.g., ≥1 operations [OR, 1.5], mechanical ventilation [OR, 1.6]), and
  • died from their injuries (OR, 2.3).

Cognitive Behavioral Therapy

16 week RCT of cocaine-dependent methadone patients of:
  CBT vs. CM vs. CBT+CM vs. TAU
30 patients per group

Rawson et al. Arch Gen Psychiatry. 2002
Cognitive Behavioral Therapy

Figure 5. Percentage of patients achieving 3 consecutive weeks of cocaine-free urine samples by group ($\chi^2 = 9.9; P = .02$). CBT indicates cognitive-behavioral therapy; CM, contingency management; and MMTP, methadone maintenance treatment program.
Cognitive Behavioral Therapy

Figure 6. Percentage of 30 possible cocaine-free urine samples at the 17-week, 26-week, and 52-week follow-up points. CBT indicates cognitive-behavioral therapy; CM, contingency management; and MMTP, methadone maintenance treatment program.

Rawson et al. Arch Gen Psychiatry. 2002